Research status of bevacizumab associated hypertension

VernacularTitle:贝伐珠单抗相关性高血压的研究现状
Author: Huan WANG ¹ ; Song-Tao MA ; Hong-Tao XIAO ; Yan CHEN ; Jun YIN ; Ke XU ; Kai CHENG
Author Information

1. 成都医学院药学院,四川成都 610500
Keywords: bevacizumab; vascular growth factor; anti-tumor angiogenesis; adverse drug reaction; hypertension; prevention and treatment
From: The Chinese Journal of Clinical Pharmacology 2024;40(5):763-767
CountryChina
Language:Chinese
Abstract: Objective Bevacizumab has been clinically used in colorectal cancer,ovarian cancer,cervical cancer,non-small cell lung cancer and other tumor diseases.Common adverse reactions during bevacizumab treatment include albuminuria,thrombosis,bleeding,gastrointestinal perforation and hypertension,among which the incidence of hypertension is as high as 19％-47％.The occurrence of hypertension affects the quality of life of patients,hinds the normal development of tumor treatment,and even induces serious cardiovascular diseases and increases the risk of death,which requires clinical attention.In this paper,the mechanism,influencing factors,prognosis and related treatment of bevacizumab associated hypertension were reviewed,so as to provide reference for clinical rational drug use.